Browsing by Author "Budak, Ferah Ah"
Now showing 1 - 8 of 8
- Results Per Page
- Sort Options
Item Assessment of cervicovaginal vascular endothelial growth factor in predicting preterm delivery(Wiley, 2014-02-23) Üstünyurt, Emin; Yilmaz, Emel M.; Küçükkömürcü, Şakir; Budak, Ferah Ah; Özkaya, Güven; Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-0297-846X; 0000-0001-7625-9148; 0000-0002-3894-1231; A-4421-2016; F-4657-2014; 22037135100; 6507291599; 6701913697; 16316866500Aim: The aim of this study is to estimate the effectiveness of cervicovaginal vascular endothelial growth factor (VEGF) in predicting preterm delivery. Methods: Cervicovaginal VEGF was measured in 30 women who presented symptoms or signs of threatened preterm labor and the control group of 30 healthy pregnant patients by enzyme-linked immunoassay. Results: There was no statistically significant difference in cervicovaginal VEGF values between the threatened preterm labor group and the control group (P > 0.05). Similarly, no statistically significant difference was observed in terms of cervical length and cervicovaginal VEGF values between preterm and term-delivered groups (P > 0.05). Additionally, there was no correlation between cervicovaginal VEGF values and cervical length (P > 0.05) between the threatened preterm labor and the control groups. Conclusion: No correlation was found between cervicovaginal VEGF values and the preterm delivery. However, we believe that the roleItem Comparison of three different treatment modalities in the management of cancer cachexia(Sage Publications, 2013) Kanat, Özkan; Çubukçu, Erdem; Avcı, Nilüfer; Budak, Ferah Ah; Ercan, İlker; Canhoroz, Mustafa; Ölmez, Fatih; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.; 55881548500; 53986153800; 55390409800; 6701913697; 6603789069; 52663246200; 57225252501Aims and background. The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia. Methods. Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months. Results. The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-alpha) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study. Conclusions. MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.Item Diagnostic value of serum concentrations of high-mobility group-box protein 1 and soluble hemoglobin scavenger receptor in brucellosis(Wiley, 2013-02) Ayarcı, Ayşe Oǧuz; Yılmaz, Emel; Sığırlı, Deniz; Budak, Ferah Ah; Göral, Güher; Oral, Haluk Barbaros; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Bölümü.; 0000-0003-0463-6818; 0000-0002-3894-1231; F-4657-2014; K-7285-2012; AAA-7472-2021; 55589179100; 22037135100; 24482063400; 6701913697; 6603453166; 7004498001Both cluster of differentiation (CD)4+ and CD8+ T lymphocytes play key roles in immunity to Brucella, in part because they secrete interferon (IFN)- and activate bactericidal functions in macrophages. Therefore, use of markers of macrophage activation may have diagnostic and prognostic significance. High-mobility group-box 1 protein (HMGB1), a late-onset pro-inflammatory cytokine, is secreted by activated macrophages. Soluble hemoglobin scavenger receptor (sCD163) is a specific marker of anti-inflammatory macrophages. The aim of this study was to investigate the diagnostic value of HMGB1 and sCD163 concentrations in brucellosis and its various clinical forms. Serum HMGB1 and sCD163 concentrations in 49 brucellosis patients were compared with those in 52 healthy control subjects. Both serum HMGB1 and sCD163 concentrations were significantly higher in brucellosis patients than in healthy controls (P<0.001). There were no statistically significant differences in serum concentrations of HMGB1 and sCD163 between cases of acute, subacute and chronic brucellosis. Additionally, serum HMGB1 concentrations were positively correlated with sCD163 concentrations, whereas neither HMGB1 nor sCD163 concentrations were correlated with C-reactive protein concentrations, white cell counts or erythrocyte sedimentation rates. Therefore, serum concentrations of HMGB1 and sCD163 may be diagnostic markers for brucellosis, but neither can be used to differentiate the three different forms of this disease (acute, subacute and chronic).Item The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients(Elsevier, 2008-07) Ersoy, Canan; Kıyıcı, Sinem Kucuksaraç; Budak, Ferah Ah; Oral, Haluk Barbaros; Güçlü, Metin; Duran, Cevdet; Selimoǧlu, Hadi; Ertürk, Erdinç; Tuncel, Ercan; İmamoğlu, Şazi; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı Anabilim Dalı.; 0000-0003-0463-6818; K-7285-2012; ABI-4847-2020; F-4657-2014; AAH-8861-2021; AAJ-6536-2021; 6701485882; 12753880400; 6701913697; 7004498001; 15073842600; 12754039000; 15074185600; 7005488796; 7006929833; 6602297533The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT) + regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5 +/- 1.5 years, diabetes duration of 17.9 +/- 6.3 months and body mass index (BMI) of 31.7 +/- 0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT + REP. In the following 12 weeks, metformin (mean daily dosage of 1381 +/- 85 mg) was added. After the first period with MNT + REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial. plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in P cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT + REP, independent from its' favourable effects on BMI and glycemic control.Item Efficacy of low-dose ultraviolet A-1 phototherapy for parapsoriasis/early- stage mycosis fungoides(Wiley, 2014-01-29) Aydoğan, Kenan; Yazıcı, Serkan; Balaban , Şaduman Adım; Tilki , Işıl Günay; Budak, Ferah Ah; Sarıcaoğlu, Hayriye; Tunalı, Şükran; Bülbül, Emel Başkan; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Venereoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Ünitesi Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.; 0000-0002-0144-3263; 0000-0001-7625-9148; 0000-0002-0193-1128; AAH-1388-2021; AAH-2459-2021; F-4657-2014; AAH-6216-2021; 9739755800; 25925620000; 14046617400; 56054728500; 6701913697; 6603722836; 7004191748; 6602518817Mycosis fungoides (MF) and parapsoriasis (PP) are major dermatologic conditions for which phototherapy continues to be a successful and valuable treatment option. UVA-1 phototherapy is effective in the management of cutaneous T-cell mediated diseases. The aim of the study was to evaluate the efficacy and safety of low-dose UVA-1 phototherapy for the management of PP/early-stage MF. A total of 30 patients, diagnosed with MF (n: 19) or PP (n: 11) were enrolled to the study. All patients were managed with low-dose UVA-1 (20 or 30 J cm(-2)). Response was assessed clinically and immunohistochemically. UVA-1 treatment led to clinical and histological complete remission (CR) in 11 of 19 MF patients (57.9%), partial remission (PR) in three of 19 (15.8%), after a mean cumulative dose of 1665 (range, 860-3120) J cm(-2) and mean number of 73 exposure (range, 43-107) sessions. Five patients with PP (45.5%) showed CR, and PR was observed in six patients with PP (54.5%) after a mean cumulative dose of 1723 (range, 1060-3030) J cm(-2) and mean number of 74 exposure (range, 53-101) sessions. We conclude that low-dose UVA-1 therapy seems to be an effective, safe, and well-tolerated treatment option for patients with PP/early-stage MF.Item Increased serum hepcidin levels in Brucellosis(Clin Lab Publication, 2014) Yılmaz, Emel; Ayarcı, Ayşe Oǧuz; Sığırlı, Deniz; Torlar, Meltem Öner; Budak, Ferah Ah; Göral, Güher; Oral, Haluk Barbaros; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.; 0000-0003-0463-6818; 0000-0001-7625-9148; 0000-0002-3894-1231; K-7285-2012; F-4657-2014; AAA-7472-2021; 22037135100; 55589179100; 56436583600; 56436661700; 6701913697; 6603453166; 7004498001Background: Both CD4(+) and CD8(+) T lymphocytes play crucial roles in immunity to Brucella, in part because they secrete interferon (IFN)-gamma and activate the bactericidal functions in macrophages. Hepcidin is an antimicrobial and iron regulatory peptide produced by the liver in response to inflammation and elevated systemic iron. Recent studies suggest that circulating monocytes and resident liver macrophages may influence both basal and inflammatory expression of hepcidin and these two cell types act in concert to regulate hepcidin production during inflammation. Here, we aimed to investigate the association of hepcidin levels with Brucellosis. Methods: Serum hepcidin levels in 49 Brucellosis patients were compared with 52 healthy control subjects by commercial ELISA kit. Results: The levels of serum hepcidin were significantly higher in Brucellosis patients compared with those of healthy controls (p < 0.001). There was no statistically significant difference in serum hepcidin levels among acute, subacute, and chronic cases with Brucellosis. Hepcidin levels were positively correlated with CRP in patients with brucellosis. Conclusions: Our first results may suggest that the levels of Hepcidin may be a useful adjunct to clinical and other laboratory findings suggestive of the disease for the diagnosis of Brucellosis, but cannot be used to differentiate the three different forms of this disease (acute, subacute, and chronic).Item Pemfigusta desmoglein antikor serum düzeyleri ile direkt immünofloresan bulgularının hastalığın klinik aktivitesi ile ilişkisi(Deri ve Zührevi Hastalıklar Derneği, 2010-10-01) Yılmaz, Mediha; Başkan, Emel Bülbül; Budak, Ferah Ah; Sarıcaoğlu, Hayriye; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Deri&Zührevi Hastalıklar Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; F-4657-2014; 35148700000; 6602518817; 6701913697; 6603722836; 7004191748Background and Design: Pemphigus is an autoimmune disease that results in blistering of the skin and mucous membranes. In this study, we investigated the relationship between disease activity and remission with ELISA scores and direct immunofluorescence (IF) - two methods used for the detection of antibodies against desmoglein-1 (dsg-1) and desmoglein-3 (dsg-3) that are responsible for blister formation. Material and Method: Twenty-three pemphigus vulgaris patients and two pemphigus foliaceus patients were enrolled in the study. The serum levels of anti-dsg-1 and anti-dsg-3 antibodies were measured with ELISA before therapy and at 3, 6, and 12 month of clinical remission. Concurrently, direct IF was performed on perilesional skin during active disease and on normal buttock skin/lower lip mucosa in remission. The tests were repeated if relapse has occured. Results: Anti-dsg-1 was detected in 17 (73.9%) pemphigus vulgaris patients and anti-dsg-3 in 23 (100%) pemphigus vulgaris patients. In two pemphigus foliaceus patients, anti-dsg-1 values were positive, while anti-dsg-3 values were negative. A statistically significant correlation was seen between anti-dsg-1 antibody serum levels and skin severity scores (r: 0.577; p: 0.003), as well as between anti-dsg-3 antibody serum levels and oral mucosa severity scores (r: 0.539; p: 0.008). Direct IF results in 16 patients (84.2%) who achieved complete remission were negative. In 9 patients who relapsed, elevated serum values of anti-dsg-1 and/or anti-dsg3 were also found. Increase in serum antibody levels was detected 1-4 months before the relapse in three of them. Conclusion: In this study, we observed that serum desmoglein antibody levels correlated with disease severity and activity. In clinical remission, serial measurements of desmoglein antibodies can provide a guide for clinical follow-up and treatment modification.Item Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era(Springer, 2009-12) Ali, Rıdvan; Özkalemkaş, Fahir; Özkocaman, Vildan; Yakut, Tahsin; Nazlıoğlu, Hülya Öztürk; Budak, Ferah Ah; Pekgöz, Murat; Korkmaz, Serhat; Karkucak, Mutlu; Özçelik, Tülay; Tunalı, Ahmet; Uludağ Üniversitesi/Tıp Fakültesi Hastanesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genetik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; F-4657-2014; AAH-1854-2021; AAG-8495-2021; 7201813027; 6601912387; 6603145040; 6602802424; 57197115377; 6701913697; 36010142900; 36009787600; 35388323500; 7005424333; 6602797853Imatinib has shown significant clinical and cytogenetic success in the treatment of chronic myeloid leukemia. Although resistance has been observed in a proportion of patients, sudden blastic crisis is a rare event during imatinib therapy. We describe a 24-year-old male patient with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who developed sudden blastic crisis in the 24th month of imatinib therapy, with loss of complete cytogenetic response. At this time, the patient had splenomegaly, severe anemia, thrombocytopenia, and leukocytosis. Bone marrow aspirate revealed the presence of massive blastic infiltration with myeloid morphology. Flow cytometric analysis of the bone marrow cells showed positivity for CD45, CD34, CD13, CD33, CD19, CD41, C1361, and glycophorin-A. Trephine biopsy specimens showed 100% cellular marrow with diffuse infiltrate by blasts. A reticulin stain of the bone marrow biopsy section demonstrated severe diffuse fibrosis. Cytogenetic analysis by fluorescence in situ hybridization (FISH) revealed that 92% of the cells were positive for the BCR/ABL fusion signal and had increased copy numbers for chromosomes 8,13,19, and 21. The patient's prognosis was unfavorable. In conclusion, chronic myeloid leukemia remains complex and includes unanswered questions. The presented case with a rare event during imatinib therapy highlights the need for the continued monitoring of residual disease and the development of strategies to eliminate residual leukemia cells in patients showing a complete cytogenetic response.